Clinical Trial Update: Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the safety and immunogenicity of the Vi-CRM197 vaccine against Salmonella Typhi in healthy adults aged 18–40, with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Typhoid Fever

Drugs mentioned

• Vi-CRM197 vaccine (Vi-CRM197 conjugate vaccine)

Snippet

Sponsor: Novartis | Conditions: Typhoid Fever | Phase 1 | Status: COMPLETED | Results posted: 2012-06-13